ATI-1777

About Aclaris Therapeutics

Aclaris Therapeutics is a publicly traded biotech company dedicated to addressing unmet needs in immuno-inflammatory and dermatological conditions through targeted kinase inhibition. The company's core strategy revolves around its internal KINect® discovery platform, which has generated a pipeline of investigational compounds. Key assets include zunsemetinib (ATI-450), an oral MK2 inhibitor in Phase 2b trials for rheumatoid arthritis and psoriatic arthritis, and sofpironium bromide, a topical anticholinergic approved in Japan for primary axillary hyperhidrosis. Aclaris is navigating a strategic shift, having discontinued its earlier commercial dermatology efforts to concentrate resources on its clinical-stage pipeline.

Therapeutic Areas

Other Moderate-to-Severe Atopic Dermatitis Drugs